Latham & Watkins advised TLG Capital, a UK-based private investment company, on its equity investment in Quality Chemical Industries Limited (QCIL), a Ugandan manufacturer of anti-retroviral and anti-malaria drugs owned by the Government of Uganda, Uganda's Quality Chemicals Limited and India's Cipla Limited.
Quality Chemicals Limited and Cipla Limited joined forces to help propel Uganda's pharmaceutical industry by launching the first pharmaceutical company to manufacture anti-retroviral and anti-malaria drugs in Africa with the full support of the Government of Uganda.
The Latham & Watkins corporate team was led by Doha counsel Craig Stoehr with associate Shaheen Haji. Advice was also provided by New York corporate partner Adel Aslani-Far.
"Given our extensive experience in the global pharmaceuticals industry as well as our experience in sub-Saharan Africa, we are pleased to have advised TLG Capital on this important transaction, and are proud to be involved with such a worthwhile business. TLG Capital's investment in QCIL provides further financial and board-level management support that will help the company build on its accomplishments thus far," said Stoehr.